Viridian Therapeutics Inc. has announced an amended credit facility with Hercules Capital, Inc., giving the company access to up to $300 million in capital at its discretion, contingent upon achieving certain milestones. The amended agreement extends Viridian's interest-free payment period and replaces the company's prior credit facility with Hercules. As part of the arrangement, Viridian drew down $50 million at closing, providing $30 million in immediate capital after repaying the outstanding amount on the previous facility. This expanded access to funding is intended to support the company's commercial launches and ongoing clinical development efforts.